29 completed, 14 active not recruiting, 11 terminated, 7 recruiting. 24 Not applicable, 17 Phase 1, 17 Phase 2, 4 Early Phase 1, 2 Phase 3.
Follow Anatomic Stage IIIC Breast Cancer AJCC v8: new trials by email Literature Review of Anatomic Stage IIIC Breast Cancer AJCC v8 trials Research Report on Anatomic Stage IIIC Breast Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-22 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer Minoxidil, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2023-03-01 | 2026-03-10 |
| STEMVAC in Patients With Early Stage Triple Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim - Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | University of Washington | 33 | 2022-11-17 | 2026-07-23 |
| Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors Patient Navigation, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 21 | 2022-11-14 | 2025-03-25 |
| Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer Transcutaneous Electrical Nerve Stimulation - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Terminated | Emory University | 17 | 2022-10-19 | 2026-05-18 |
| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer Best Practice, Biopsy, Biospecimen Collection - Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma | Not applicable | Withdrawn | City of Hope Medical Center | 2022-07-03 | 2022-06-09 | |
| Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors Dietary Intervention - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Withdrawn | City of Hope Medical Center | 2022-06-15 | 2022-06-09 | |
| Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration - Breast Cancer, Anatomic Stage I Breast Cancer AJCC v8 | Not applicable | Terminated | University of Alabama at Birmingham | 27 | 2022-06-01 | 2026-05-07 |
| A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment Best Practice, Educational Intervention, Quality-of-Life Assessment - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Terminated | University of Alabama at Birmingham | 37 | 2022-06-01 | 2026-05-06 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | University of Southern California | 173 | 2021-11-24 | 2026-10-05 | |
| An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 50 | 2021-11-01 | 2025-02-07 |
| Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer Best Practice, Informational Intervention, Medical Device Usage and Evaluation - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Completed | Emory University | 33 | 2021-10-22 | 2025-06-17 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Cimetidine, Dexamethasone, Diphenhydramine - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 / Phase 3 | Completed | Ohio State University Comprehensive Cancer Center | 130 | 2021-10-07 | 2025-08-20 |
| Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 256 | 2021-07-23 | 2026-08-21 |
| Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors Best Practice, Internet-Based Intervention, Survey Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Not applicable | Active not recruiting | Ohio State University Comprehensive Cancer Center | 400 | 2021-06-28 | 2026-02-19 |
Showing 20 of 69. Sign in to see all of them.
Breast Neoplasms (16) · Triple Negative Breast Neoplasms (15) · Breast Carcinoma In Situ (9) · Ovarian Neoplasms (7) · Neoplasm Metastasis (5) · Lung Neoplasms (4) · Prostatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Inflammatory Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Intraductal, Noninfiltrating (2)
Neoplasms (42) · Neoplasms by Site (41) · Breast Diseases (34) · Skin Diseases (34) · Skin and Connective Tissue Diseases (34) · Breast Neoplasms (18) · Neoplasms by Histologic Type (15) · Carcinoma (14) · Neoplasms, Glandular and Epithelial (14) · Genital Diseases (11) · Urogenital Diseases (11) · Carcinoma in Situ (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases, Female (9)
Practice Guidelines as Topic (10) · Standard of Care (9) · Taxes (9) · Paclitaxel (6) · Albumin-Bound Paclitaxel (4) · Interviews as Topic (4) · Letrozole (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · pembrolizumab (4) · 130-nm albumin-bound paclitaxel (3) · Anastrozole (3) · Biopsy (3) · Carboplatin (3) · Cyclophosphamide (3)
M.D. Anderson Cancer Center (21) · Ohio State University Comprehensive Cancer Center (10) · Mayo Clinic (9) · Emory University (3) · Fred Hutchinson Cancer Center (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Jonsson Comprehensive Cancer Center (2) · Thomas Jefferson University (2) · University of Alabama at Birmingham (2) · University of California, San Francisco (2) · University of Southern California (2) · Wake Forest University Health Sciences (2) · Alliance for Clinical Trials in Oncology (1) · ECOG-ACRIN Cancer Research Group (1)
United States (62) · Puerto Rico (2) · Chile (1) · Colombia (1) · Mexico (1) · Uganda (1)
Meghan Karuturi (3) · Senthilkumar Damodaran (2) · Timiya Nolan, PhD (2) · Abenaa M Brewster (1) · Alison M Schram (1) · Amy J Chien, MD (1) · Anita H. Chen, M.D. (1) · Apostolia M Tsimberidou (1) · Azadeh Nasrazad, MD,PHD (1) · Banu Arun (1) · Bora Lim, MD (1) · Brent A. Bauer, M.D. (1) · Brian C Focht, PhD (1) · Bridget A Oppong, MD (1) · Brittany L Dulmage, MD (1)
PMID 33142018, PMID 35727609, PMID 35788100, PMID 36336249, PMID 36351402, PMID 36609349, PMID 36658425, PMID 37823909, PMID 38828938, PMID 39325778, PMID 39865083, PMID 40939237, PMID 40966714, PMID 41271741, PMID 42804742
P30CA138292 (3), P30CA012197 (2), P30CA014089 (2), P30CA033572 (2), K08CA245208 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA016672 (1), P50CA116201 (1), R01CA105023 (1), R01CA222246 (1), R01CA237046 (1), R01CA238946 (1), R37CA256867 (1)